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Abstract: Biological therapies, such as monoclonal antibodies (mAbs) that target 
  tumor-associated antigens have been considered an effective therapeutic approach in   oncology. 
In considering Notch-1 receptor as a potential target, we performed immunohistochemistry 
on tissue microarrays to determine 1) whether the receptor is overexpressed in tumor cells 
as compared to their corresponding normal tissues and 2) the clinical significance of its 
  expression levels in human breast, colorectal, lung and prostate cancers. We found that the 
expression of Notch-1 protein was overexpressed in primary colorectal adenocarcinoma and 
nonsmall cell lung   carcinoma (NSCLC), but not in primary ductal breast carcinoma or prostate 
  adenocarcinoma. Further analysis revealed that higher levels of Notch-1 protein expression were 
significantly associated with poorer differentiation of breast and prostate tumors. Strikingly, 
for NSCLC, the expression levels of Notch-1 protein were found to be inversely correlated 
with tumor   differentiation and progression. For colorectal tumors, however, no correlation of 
Notch-1 protein expression was found with any tumor clinicopathological parameters, in spite 
of its overexpression in tumor cells. Our data demonstrated the complexity of Notch-1 protein 
expression in human solid tumors and further supported the notion that the roles of Notch-1 
expression in tumorigenesis are highly context-dependent. The findings could provide the basis 
for development of distinct therapeutic strategies of Notch-1 mAbs for its applications in the 
treatment of suitable types of human cancers.
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Introduction
The Notch family of receptors plays a crucial role in cell self-renewal, cell fate 
  determination, cell division and apoptosis. Mammals have four Notch receptors 
(Notch-1, -2, -3, and -4) for five Notch ligands (DLL1, 3, 4 and Jagged 1, 2). The Notch 
receptors differ in the number of epidermal growth factor-like repeats present and the 
length of the intracellular domain. Notch signaling has also been shown to play a role 
in the regulation of remodeling of the vascular network.1–3 Tumor development is a 
cellular process that is partly driven by alterations in cell fate. Deregulated   expression 
of Notch receptors and ligands is observed in a variety of solid tumors, including 
  cervical, skin, pancreatic, ovarian, lung, prostate, and breast carcinomas.4–15 High-level 
expression of Notch-1 and Jagged-1 mRNAs is associated with both poor prognosis in 
breast cancer and metastasis in prostate cancer.11–13 Hodgkin’s lymphomas, anaplastic 
large-cell non-Hodgkin’s lymphomas, and some acute myeloid leukemias also show 
deregulated expression of Notch receptors or ligands.16–20 Interestingly, recent data 
suggests that Notch-1 is downregulated in late stage human papilloma virus-infected Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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tumors.21 Similar observations are also documented in small 
cell lung cancer and prostate adenocarcinomas.14,22 Therefore, 
the exact role of Notch signaling during tumorigenesis of 
various cancers remains controversial.
Targeted therapies have become a major focus for cancer 
research. Since the clinical application of imatinib23 for the 
treatment of chronic myeloid leukemia, biological therapies 
that target tumor-associated antigens have raised hopes for 
improved survival outcomes in many cancers.24 Many tumor 
antigens recognized by monoclonal antibodies (mAbs) are 
expressed not only by malignant cells, but also by normal 
cells.24,25 Therefore, the best target for a therapeutic antigen 
is one that is highly expressed by tumor cells while only 
  minimally expressed by normal cells from which tumors arise, 
such as the epithelial cells. For instance, the   tyrosine-kinase 
receptor HER-2 is strongly expressed (determined by immu-
nohistochemical analysis) in 30% of diagnosed breast cancer 
patients, while only weakly expressed in the luminal epithelial 
cells of normal breast tissue determined by immunohis-
tochemical analysis.26 This overexpression is associated with 
an unfavorable prognosis of the breast cancer patients.27 Breast 
cancer patients whose tumors overexpress the HER-2 receptor 
derive most clinical benefits from trastuzumab, a therapeutic 
mAb targeting the HER-2 receptor.28
To assess whether the Notch-1 receptor is a candidate 
for the development of targeted therapeutic antibodies, we 
sought to systemically investigate the expression profiles of 
the Notch-1 protein in tumor cells and its correlation with 
the cancer patient’s prognosis.
Materials and methods
Tissue microarrays (TMAs)
TMAs of four major types of tumors (breast, colorectum, 
lung, and prostate) and their corresponding normal tissues 
were purchased from multiple TMA suppliers including 
Accurate Chemical and Scientific Corp. (West Bury, NY, 
USA); Biochain Institute, Inc. (Hayward, CA, USA); US 
Biomax, Inc. (Rockville, MD, USA); BioVintage, Inc. (San 
Diego, CA, USA); and Imgenex Corp. (San Diego, CA, 
USA). We also obtained normal human organ TMA (Catalog 
# FDA993; US Biomax) with 33 types of organs taken from 
3 normal human individuals including 30 types recommended 
by the US Food and Drug Administration.
Breast
The 408 breast tumor samples were obtained from 4 men 
and 404 women, ranging in age from 23 to 87 years (median 
at 48 years) at surgery. Histologically, there were 367 cases 
of invasive ductal carcinoma (90%), 29 cases of invasive 
lobular carcinoma (7%), and 11 cases of other tumor types 
(3%). There were a total of 79 normal breast samples from 
1 man and 78 women, ranging in age from 18 to 71 years 
(median at 43 years). Thirty-three (42%) were cancer   adjacent 
normal breast tissue and 46 (58%) were from noncancer 
individuals.
colorectum
The 511 colorectal tumor samples were collected from 
328 men and 183 women with median age at surgery of 
58 years (ranging from 20 to 87 years). Overall, 462 patients 
(90%) had colon cancer and 49 (10%) had rectal cancer. The 
vast majority (499 cases) were histologically   adenocarcinoma 
(98%), the remaining 12 cases (2%) being mucinous car-
cinomas. Additionally, 194 normal colorectal tissues were 
obtained from 132 men and 62 women with median age of 
56 (  ranging from 13 to 87 years); of which, 141 (73%) samples 
were cancer-adjacent normal colorectal tissues and 53 (27%) 
were colorectal tissues from noncancer individuals.
Lung
The 429 lung tumor samples were biopsied from 311 men and 
118 women ranging from 28 to 89 years (median at 59 years) 
at the time of surgery. The most common   histological type 
was nonsmall cell lung cancer (NSCLC) (92%, 395 samples), 
including 195 adenocarcinoma (49%) and 200 squamous cell 
carcinoma (51%). The remaining 34 cases were small cell lung 
carcinoma (SCLC, 8%). There were 68 normal lung tissues 
collected from 53 men and 15 women ranging from 21 to 
81 years (median at 58 years); of which 58 (85%) samples 
were cancer adjacent normal lung tissues and 10 (15%) were 
noncancer individual lung tissues.
Prostate
The age of 227 prostate cancer patients ranged from 20 to 
89 years (median age of 66 years). Almost all tumors (225) were 
adenocarcinma (99%), with only 2 tumors being   transitional 
cell carcinoma (1%). The 128 normal prostate tissues were 
made up of 66 (52%) cancer adjacent normal prostate tissues 
and 62 (48%) prostate tissues from noncancer men. Their ages 
spanned from 19 to 86 yeas with median age of 64 years.
Generation of Flp-In™ T-REx™ 293 cell 
line stably expressing human Notch-1
The full-length Notch-1 coding region tagged with C-terminal 
end FLAG peptide was chemically synthesized at DNA 
2.0 (Menlo Park, CA, USA). Flanking sequences   contained Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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5’   HindIII and 3’ NotI which were used for directional 
  restriction cloning into pcDNA™ 5/FRT/TO (Invitrogen 
Corporation, Carlsbad, CA, USA) expression vector. Flp-In™ 
T-REx™ 293 cells (Invitrogen) contain a single genomic 
FRT (Flp [  Flippase] recombinase target) site and express the 
Tet   repressor which allows for the construction of isogenic 
recombinants under tetracycline control.   Tetracycline-inducible 
stable expression cell lines were generated by cotransfecting 
pcDNA5/FRT/TO-HN1 + FLAG and pOG44 (Invitrogen), 
a plasmid encoding FLP recombinase, in a 1:9 ratio into 
Flp-In 293 T-REx using FuGENE™ 6 (Roche Diagnostics 
  Corporation, Indianapolis, IN, USA)   transfection reagent as 
per   manufacturer’s   recommendations. Cell lines with stably 
integrated cDNAs were then selected with hygromycin B 
(100 µg/mL) (Mediatech, Inc.,   Manassas, VA, USA) and 
were expanded. Expression levels of the Notch proteins were 
assessed by immunohistochemical (IHC) staining, Western 
blotting, and flow cytometry.
Paraffin embedment of Notch-1-
transfected cells
Actively growing Notch-1 stably transfected Flp-In™ 
T-REx™-293 cells were induced by doxycycline (2 µg/mL) 
for 48 hours and harvested through trypsinization. The cell 
pellets were then fixed in 10% neutral buffered formalin 
(  ThermoFisher, Pittsburgh, PA, USA) for 16–24 hours. 
The cells were processed with 70% ethanol, 95% ethanol, 
100% ethanol, xylenes, and paraffin in a tissue processor 
(Sakura, Torrance, CA, USA). The cells were then   embedded 
in   paraffin, cut into 5 µm sections, and mounted onto 
  Superfrost® Plus glass slides (ThermoFisher).
Western blotting
Cell lysates from full-length Notch-1-transfected Flp-In™ 
T-REx™-293 cells, with or without induction of   doxycycline 
(2 µg/mL) were resolved by sodium dodecyl sulfate 
  polyacrylamide gel electrophoresis (SDS-PAGE) on a 3%–8% 
Tris-Acetate gel (Invitrogen) and transferred to   nitrocellulose 
membrane using the iBlot system (Invitrogen). The blots were 
blocked overnight (16–20 hours) at 4°C in a 1% bovine serum 
albumin-containing 1X Tris-Tween buffered saline (TTBS) 
solution. After two rinses with 1X TTBS, the blots were 
incubated with rabbit anti-Notch-1 polyclonal antibody (Cat. 
# sc-6014-R; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA) at a concentration of 1 µg/mL for 2 hours. After 
six 5-minute washes in 1X TTBS, the blots were   incubated 
with goat-anti-rabbit-HRP (R&D Systems, Inc., Minneapo-
lis, MN, USA) at a 1:2000 dilution for 1 hour,   followed by 
six more 5-minute washes with 1X TTBS. Antibody binding 
was detected by an enhanced chemiluminescence kit (Pierce 
Biotechnology, Inc., Rockford, IL, USA).
immunohistochemistry
Paraffin embedded cell or tissue sections were deparaffinized 
by incubation at 60°C overnight followed by immersion in 
two changes of xylene (ThermoFisher) and two changes of 
absolute ethanol (Pharmco Products Inc., Brookfield, CT, 
USA), and rehydrated in distilled water. Antigen retrieval was 
performed in a calibrated steam pressure cooker (Decloaking 
Chamber, BioCare Medical, Walnut Creek, CA, USA) for 
30 seconds at 125°C in 1X Target Retrieval Solution (Dako-
Cytomation, Carpinteria, CA, USA). All additional steps 
(unless   specified) were done at room temperature in a hydrated 
chamber. Endogenous peroxidase was blocked with peroxidase 
block from an EnVision™ + Rabbit Kit (DakoCytomation) for 
10 minutes. The slides were also immersed in 5% nonfat dry 
milk for 30 minutes to minimize nonspecific binding due to 
hydrophobic interaction. The slides were then incubated with 
the rabbit anti-Notch-1 polyclonal antibody overnight at 4°C 
followed by labeled polymer from an EnVision + Rabbit Kit for 
30 minutes. The slides were developed with diaminobenzidine 
and hydrogen peroxidase for 3 minutes and counterstained with 
hematoxylin (Sigma-Aldrich, St. Louis, MO, USA).
scoring system and statistical analysis
The semi-quantitative method of staining intensity of Notch-1 
protein on normal and tumor cells was manually scored as 
negative (–, no staining), weak (+), moderate (++), and strong 
(+++) by two of the investigators (YL and JB) according to a 
prespecified intensity scale, with discrepancies agreed upon 
by consensus. Representative examples for the different 
scores are provided in Figure 1.
The chi-square test was used to determine the   differentiation 
of Notch-1 expression between cancer patients and normal pop-
ulation. It was also used in   analyzing the   clinicopathological 
correlations for parameters with two   categories. When 
  evaluating their associations to tumor stage and grade, 
a   chi-square test for trend is utilized. A P-value of less than 
0.05 was considered to indicate statistical significance. All 
tests were performed using GraphPad Prism (version 5.01 for 
Windows; GraphPad Software, San Diego, CA, USA).
Results
Characterization of Notch-1 antibody
We first tested the specificity of commercially available Notch-1 
antibody on Western blots containing whole cell   protein extracts Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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from Notch-1-transfected Flp-In™ T-REx™-293 cells with 
or without doxycycline induction. Immunostaining with the 
polyclonal rabbit antibody against the cytoplasmic domain of 
Notch-1 revealed a strong cross-reactive   protein of the expected 
size of Notch-1 receptor, especially in the cell protein extracts 
from the cells stimulated with doxycycline (Figure 1A). The 
specificity of the antibody was further   confirmed by immuno-
histochemical staining on the cells embedded in   paraffin, show-
ing membranous as well as   cytoplasmic staining of Notch-1 
receptor on the transfected Flp-In™ T-REx™-293 cells induced 
by doxycycline (Figure 1B).
Expression of Notch-1 protein  
was significantly upregulated  
in primary colorectal and lung but  
not in breast or prostate tumors
To determine whether Notch-1 protein is overexpressed in 
breast, colorectal, lung, and prostate tumors in comparison 
with their corresponding normal tissues, immunohistochem-
istry was performed on a number of tissue microarrays con-
sisting of a large number of tumor and corresponding normal 
tissues. We compared the expression profiles of Notch-1 
protein between tumor cells and the luminal epithelial cells 
of adjacent normal tissues to see whether the receptor was 
  overexpressed in tumor cells. We found that Notch-1 protein 
was detected in the majority of breast tumors (largely consisted 
of ductal breast carcinomas) and normal breast tissues (ductal 
epithelial cells) (Figure 2 and Table 1). However, there was no 
difference in Notch-1 protein expression   levels between breast 
tumor and   normal tissues (P = 0.2896). Unlike breast tumors, 
the overall   expression of Notch-1   protein was significantly 
higher in colorectal   adenocarcinoma as   compared to the nor-
mal colorectal epithelial cells (P = 0.0005). Noticeably, there 
were 61 (12%) of colorectal adenocarcinoma versus 6 (3%) 
of normal colorectum with moderate to strong expression 
of Notch-1 protein (Table 1). Similarly, the overall Notch-1 
protein expression was significantly higher in primary lung 
tumors (consisting mainly of NSCLC) than in normal lung 
tissues (bronchial luminal epithelial cells) (Table 1). Notch-1 
protein was detected in 74% of lung tumors while only in 47% 
of normal lung tissues. In addition, more lung tumor tissues 
showed stronger reactivity (moderate staining intensity) to 
Notch-1 protein than normal lung tissues did (12% vs 0%). 
Notch-1 protein expression was also detectable in the major-
ity of prostate adenocarcinoma and adjacent normal prostate 
tissues. However, there was no significant up-regulation of 
Notch-1 protein in prostate tumors (P = 0.1309; Table 1).
Notch-1 protein was highly 
overexpressed in squamous  
cell lung carcinoma of NSCLC
Among the lung cancer samples available for this study, we 
found that the most common histological type was NSCLC 
(92% of 429 samples), consisting of 195 adenocarcinoma and 
200 squamous cell carcinoma. The remaining 34 samples were 
SCLC (8% of 429 samples). SCLC showed higher number of 
negative samples than normal samples (68% in SCLC vs 53% 
in normal tissues), suggesting that SCLC patients might not 
benefit from Notch-1 antibody-based therapies. In contrast, 
we found remarkably that 77% of NSCLC compared to 47% 
of normal tissues and only 32% of SCLC were positive for 
Notch-1 protein (P , 0.001; Figure 3). Moreover, within the 
− + − +
400 kDa
116 kDa
AB
Figure 1 Specificity of the anti-Notch-1 antibody. A) Western blots. The cell lysates from full-length Notch-1-transfected Flp-In™· T-REx™ 293 cells, both doxycycline 
(DOX)-uninduced (–) and induced (+) were used to test the specificity of the rabbit anti-Notch-1 antibody. The cross-reactive protein of Notch-1 transmembrane protein of 
full-length (300 KD) and truncated (120 KD) forms were visualized by enhanced chemiluminescence. B) Immunocytochemistry. Paraffin sections of DOX-uninduced (–) and 
induced (+) Notch-1-transfected Flp-In T-REx-293 cells were stained with antibody showing the membranous and cytoplasmic staining of Notch-1 in DOX-induced cells.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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NSCLC tumor samples, higher expression of Notch-1 protein 
was recorded in 22% of the squamous cell carcinoma group 
but not the adenocarcinoma group that showed only 3% of 
the samples displaying stronger reactivity. The difference was 
highly statistically significant (P , 0.0001; Figure 3).
Correlation of Notch-1 expression 
levels with tumor clinicopathological 
parameters
To understand the clinical significance of Notch-1 protein 
expression in tumors, we sought to determine whether the 
levels of Notch-1 protein expression correlate with tumor 
  clinicopathological parameters. We categorized the   staining 
intensities into high and low expression groups. High   expression 
group represented strong and/or moderate staining and low 
expression group represented weak and/or negative staining. 
The expression profiles of Notch-1 protein in tumors were 
directly analyzed with these parameters to see whether there 
was a correlation. For breast tumors, the higher levels of 
Notch-1 protein expression were significantly correlated with 
  poorly-differentiated and estrogen   receptor-positive breast 
tumors (P = 0.0067 and 0.0134, respectively). No statistical dif-
ferences were observed with age,   pathological stages, or proges-
terone receptor status (Table 2). For   colorectal tumors, the levels 
of Notch-1 protein expression were not associated with age, 
gender, pathological stages or tumor grades. For lung tumors, 
the levels of Notch-1 protein expression were significantly 
higher in male patients than in female patients (P = 0.0526). 
Remarkably, the levels of Notch-1 protein   expression were 
inversely correlated with tumor grades and pathological stages 
(Table 2). Lower levels of Notch-1 protein expression was sig-
nificantly associated with poorly-  differentiated tumors and later 
stages of tumors with more advanced local invasion, regional 
lymph node, and distal metastasis (P = 0.0047 and 0.0019, 
respectively; Table 2). For prostate tumors, higher levels of 
Notch-1 protein expression were significantly associated 
with higher Gleason scores (P = 0.0081). No correlation was 
observed with age or pathological stages (Table 2).
Normal breast (weak) Normal lung (weak) Normal colon (negative)
Breast tumor (weak) Colon tumor (moderate) Lung tumor (moderate)
Figure 2 representative images of Notch-1 protein expression in breast, colorectal and lung tumors and their adjacent noncancer lung tissues. Negative: no staining; weak: 
weak staining; moderate: moderate staining. Original magnification, 400X.
Table 1 Expression of Notch-1 in primary tumors and corresponding 
noncancer tissues
Sample  
size
Staining intensity  
(%)
P
+++ ++ + -
Breast Tumor 408 0 15 78 6 0.2896
normal 79 0 19 80 1
colorectum Tumor 511 1 11 59 30 0.0005
normal 194 0 3 74 23
Lung Tumor 429 0 12 62 27 ,0.0001
normal 68 0 0 47 53
Prostate Tumor 227 0 7 75 18 0.1309
normal 128 0 11 79 10
Notes: staining intensity: +++, strong; ++, moderate; +, weak; –, no staining.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Notch-1 protein expression  
was widely detectable in endothelial  
cells of vasculature
Notch signaling plays a role during vascular development 
as well as during maintenance of vessel homeostasis in the 
adult.3 It was found that Notch-1, -3, and -4 are all expressed 
in arteries.3 Endothelial cells express Notch-1 and -4 where 
as pericytes express Notch-1 and -3.29 In the current study, 
we surveyed 33 types of human normal tissues/organs 
to   determine the distribution pattern of Notch-1 protein 
  expression. We found that Notch-1 protein expression was 
essentially detectable in all tissues, predominantly in vascu-
lature,   consistent with previous reports.1,2 Further analysis 
showed that Notch-1 protein was mainly expressed on the 
endothelial cells of vasculature as well as on capillaries, such 
as in lung tissue (Figures 4A and 4C). Moreover, Notch-1 
protein expression was widely detected on the endothelial 
cells of vasculature within tumors (Figures 4B and 4D).
Discussion
Accumulating preclinical and clinical evidence supports a pro-
oncogenic function for Notch signaling in several solid tumors, 
particularly in breast cancer.30–35 A high level of Notch-1 mRNA 
expression has been linked with a poorer prognosis for breast 
cancer patients.11,12 Notch-1 protein expression in breast cancer 
tissues generally exhibits a higher and more widespread levels 
of Notch-1 protein than in the noncancer breast tissue (luminal 
ductal epithelial cells).11,35,36 However, these observations were 
largely based on the limited numbers of breast tumor and non-
cancer breast samples. We compared the expression profiles of 
Notch-1 protein in a larger number of breast tumor and noncan-
cer breast tissue samples (408 and 79, respectively). We were 
surprised to find that there was no evidence of overexpression of 
Notch-1 protein in breast tumor cells as compared to the luminal 
epithelial cells of noncancer breast tissue. However, further 
analysis of correlation between Notch-1 protein expression and 
tumor clinicopathological parameters revealed that the higher 
levels of Notch-1 protein expression was actually associated with 
poorly-differentiated tumors. Similarly, no overexpression of 
Notch-1 protein was found in prostate tumors, but higher levels 
of Notch-1 protein were significantly associated with prostate 
tumors with poorer prognosis. Our findings suggest that over-
expression of Notch-1 protein is not essential for the onset and 
maintenance of breast or prostate cancers. Instead, the activation 
status of Notch-1 receptor may play a more important role. It is 
possible that the activation levels of Notch-1 receptor are higher 
in tumor cells than in the luminal epithelial cells of noncancer 
breast and prostate tissues. Further studies examining the protein 
expression levels of the downstream Notch signaling compo-
nents, such as Hes-1, may be useful to verify this hypothesis.
Notch signaling components are widely distributed 
in adult gut tissues and Notch signaling is considered a 
  gatekeeper of intestinal progenitor cells.37–39 It has been dem-
onstrated that a highly conserved expression pattern exists 
between colon crypt cell progenitors and colorectal cancer 
cells, suggesting a role of Notch activation in   proliferating 
100%
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40%
20%
0%
Normal
lung (68)
Total lung
tumor (429)
SCLC
(34)
NSCLC
(395)
AC
(195)
SCC
(200)
Negative
Weak
Moderate
P < 0.0001 P < 0.0001 P < 0.0001
Figure 3 Significant overexpression of Notch-1 protein in lung tumors. Notch-1 protein was overexpressed in lung tumors (mainly in nonsmall cell lung carcinoma [NSCLC] 
but not small cell lung carcinoma [SCLC]). The overexpression was predominantly observed in squamous cell carcinoma (SCC), but not in adenocarcinoma (AC).Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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adenoma cells.40 This hypothesis was confirmed by a study in 
which treatment of multiple intestinal neoplasia mice   carrying 
a heterozygous mutation of the APC tumor   suppressor gene 
with γ-secretase inhibitors induces goblet cell differentiation 
and reduces proliferation in such adenoma.41 However, the 
exact role of Notch-1 protein expression remains unclear 
in human colorectal cancer tumorigenesis. In the present 
study, we found that the Notch-1 protein was overexpressed 
in colorectal adenocarcinoma as compared to noncancer 
  colorectal tissue. Unexpectedly, further analysis revealed that 
the expression levels of Notch-1 protein did not correlate with 
the tumor clinicopathological parameters used in this study, 
such as tumor grades and pathological stages. The findings 
suggest that in colorectal tumor cells, Notch-1 signaling is 
probably not physiologically activated, or that its activation 
has minimal impact on clinicopathological   parameters. It is 
also possible that other Notch signaling components (such as 
Jagged-1, Jagged-2, or Notch-2 receptor) play more impor-
tant roles in colorectal tumorigenesis.38
The role of Notch signaling in human lung cancer still 
remains unclear although it has been shown that it plays an 
important role in fetal lung development by regulating airway 
epithelial development.42 Notch-1 mutation in transgenic 
mice proved to be embryonic lethal at day 11.43 Several 
in vitro studies have suggested that Notch-1 activation may 
play the tumor growth promotion and inhibition roles for 
NSCLC and SCLC tumorigenesis, respectively.22,44 Our data 
showed that Notch-1 protein was significantly   overexpressed 
in NSCLC (mainly in squamous cell   carcinoma) but 
only weakly expressed in SCLC, consistent with other’s 
  observations.42 However, we were surprised to find that 
the elevated levels of Notch-1 protein expression were 
  associated with well-  differentiated tumors as well as tumors 
with   favorable prognosis (mainly in NSCLC). This inverse 
correlation suggests that like SCLC, high levels of Notch-1 
protein expression may play a tumor growth inhibitive role 
in tumor differentiation, as well as metastasis of NSCLC.
Taken together, our data demonstrate the complexity of 
Notch-1 protein expression in four major types of tumors 
and further support the notion that the roles of Notch-1 
expression in human solid tumor pathogenesis are highly 
context-dependent. These results, thus, may be able to assist 
Table 2 Correlation of expression levels of Notch-1 protein with tumor clinicopathological parameters
Breast Colorectum Lung Prostate
High Low P High Low P High Low P High Low P
Age
 , Median 28 152 0.9030 30 212 0.4059 18 189 0.0651 10 91 0.1328
 $ Median 36 189 27 241 32 190 6 120
Gender
  Male 0 4 0.3860 39 289 0.4794 42 269 0.0526 16 211 –
  Female 64 340 18 165 8 110 0 0
Stage
 i 2 12 0.6078 3 28 0.3427 21 70 0.0019 0 0 0.2313
  ii 27 109 21 146 14 117 7 135
  iii 16 77 22 133 13 76 5 34
  iV 5 12 11 58 0 43 1 13
Tumor grade
 1 1 23 0.0067 13 104 0.1835 16 55 0.0047 – – –
 2 33 178 39 237 17 143 – –
 3 22 64 4 75 10 108 – –
 4 0 0 0 8 0 6 – –
Gleason score
  2–4 – – – – – – – – – 0 10 0.0081
  5–6 – – – – – – 0 31
 7 – – – – – – 2 58
  8–10 – – – – – – 11 81
Estrogen receptor
  negative 3 37 0.0134 – – – – – – – – –
  Positive 17 45 – – – – – –
Progesterone receptor
  negative 10 40 0.9606 – – – – – – – – –
  Positive 10 41 – – – – – –
Notes: High, combination of strong and moderate. Low, combination of weak and negative. Median, median ages for breast, colorectum, lung, and prostate cancer patients 
were 48, 58, 59, and 66 years, respectively.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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in the design, development and selection of tumor types for 
targeting of Notch-1 therapeutic mAbs. For instance, the 
Notch-1 antagonist mAbs may be more suitable for breast 
and prostate cancers with high levels of Notch-1 protein 
expression. On the other hand, the agonist mAbs could be 
useful for the treatment of lung cancers in both NSCLC and 
SCLC. It is worth noting, that unlike DLL4 mAbs, Notch-1 
mAbs may present some challenges for targeted therapies 
to diseased tissues as we, along with others,1–3,45 observed a 
widespread expression of Notch-1 protein on endothelial cells 
of vasculatures in both tumor and noncancer tissues.
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